866-997-4948(US-Canada Toll Free)

Afatinib (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Non Small Cell Lung Cancer

No. of Pages : 33 Pages

 

GlobalDatas pharmaceuticals report, Afatinib (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020 provides Afatinib sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Non Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData\'s team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Afatinib including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Afatinib including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2013-2020 for Afatinib in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 4


2 Introduction 5
2.1 NSCLC Market 5
2.2 Epidemology 5
2.3 Etiology 7
2.3.1 Tobacco 7
2.3.2 Radon 7
2.3.3 Asbestos 8
2.3.4 Other Environmental Agents 8
2.4 GlobalData Pipeline Report Guidance 9


3 NSCLC Disease Market: Market Characterization 10
3.1 NSCLC Disease Market 10
3.2 NSCLC Disease Market Forecast and CAGR 10
3.3 Drivers for the RCC Disease Market 11
3.3.1 High Incidence 11
3.3.2 High Mortality Rate 12
3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 12
3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 12
3.3.5 Promising Pipeline Drugs 12


4 TNM Classification of NSCLC 13


5 Afatinib 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies 16
5.4 Approval History of Afatinib 17
5.5 Factors Effecting the Sales of Afatinib 17
5.5.1 NSCLC Market 17
5.5.2 Fast Track Designation 17
5.5.3 Superior Efficacy 17
5.5.4 Oral administration 17
5.6 Drug Risk Benefit Score 18
5.7 Intensity of Competition 18
5.8 Sales forecast 19
5.8.1 Target patient Pool of Afatinib 19
5.8.2 Dosing 19
5.8.3 Market Penetration 20
5.8.4 Annual Cost of Therapy 20
5.8.5 Sales Projections of Afatinib 20


6 NSCLC Market: Appendix 29
6.1 Market Definitions 29
6.2 Abbreviations 29
6.3 Research Methodology 29
6.3.1 Coverage 30
6.3.2 Secondary Research 30
6.3.3 Forecasting 30
6.3.4 Number of Patients Approved to take the Drug 30
6.3.5 Net Penetration of Drug 31
6.3.6 Net Annual Dosing 32
6.3.7 Annual Cost of Therapy 32
6.3.8 Primary Research 32
6.3.9 Expert Panels 32
6.4 Contact Us 33
6.5 Disclaimer 33
6.6 Sources 33

List of Table


Table 1: NSCLC, Incidences and Mortality, 20082030 5
Table 2: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Table 3:Afatinib Approval history 16
Table 4: Drug Risk Benefit Score (DRB)-Afatinib 17
Table 5: Afatinib, NSCLC, Global Sales Forecast ($m), 20132020 19
Table 6: Afatinib, NSCLC, The US, Sales Forecast ($m), 20132020 20
Table 7: Afatinib, NSCLC, The UK, Sales Forecast ($m), 20132020 21
Table 8: Afatinib, NSCLC, France, Forecast ($m), 20132020 22
Table 9: Afatinib, NSCLC, Germany, Sales Forecast ($m), 20132020 23
Table 10: Afatinib, NSCLC, Italy, Sales Forecast ($m), 20132020 24
Table 11: Afatinib, NSCLC,Spain, Sales Forecast ($m), 20132020 25
Table 12: Afatinib, NSCLC,Japan, Sales Forecast ($m), 20132020 26

List of Chart


Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: Percentage Difference of Incidence and Mortality of Top 20 Cancers 5
Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6
Figure 4: % Share of Risk Factors in Developed Countries 7
Figure 5: Per Capita Cigarette Consumption, The US, 1976-2006 8
Figure 6: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Figure 7: Oncology, Global, Incidence (in millions), 2008-2030 10
Figure 8: NSCLC, Global, Incidence (in millions), 2008-2030 10
Figure 9: Broad Classification of NSCLC 12
Figure 10: Detailed TNM Classification 13
Figure 11: Classification of NSCLC 14
Figure 12: Drug Model Diagram of Afatinib 18
Figure 13: Afatinib, NSCLC, Global Sales Forecast ($m), 20132020 19
Figure 14: Afatinib, NSCLC, The US,Sales Forecast ($m), 20132020 20
Figure 15: Afatinib, NSCLC, The UK, Sales Forecast ($m), 20132020 21
Figure 16: Afatinib, NSCLC, France, Forecast ($m), 20132020 22
Figure 17: Afatinib, NSCLC, Germany, Sales Forecast ($m), 20132020 23
Figure 18: Afatinib, NSCLC, Italy, Sales Forecast ($m), 20132020 24
Figure 19: Afatinib, NSCLC,Spain, Sales Forecast ($m), 20132020 25
Figure 20: Afatinib, NSCLC,Japan, Sales Forecast ($m), 20132020 26
Figure 21 : Afatinib, NSCLC, Global Sales Distribution by Country ($ mn), 2020 27
Figure 22: GlobalData Methodology 28
Figure 23: Drug Model Diagram 30
Figure 24: Patients Approved for the Drug 31

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *